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A promising strategy for the treatment of genetic diseases, pharmacological chaperone therapy, has been proposed
recently. It exploits small molecules which can be administered orally, reach difficult tissues such as the brain and
have low cost. This strategy has a vast field of application. In order to make drug development as fast as possible, it
is important to exploit drug repositioning. We evaluated the impact and limitations of this approach for rare
diseases and we provide a shortcut in finding drugs for off-target usage.
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A large share of mutations associated to human diseases
causes the destabilization of specific proteins. The activ-
ity of unstable proteins can be rescued by small mole-
cules that act as pharmacological chaperones (PC).
Usually PC are inhibitors or antagonists of their targets
used at a very low concentration, but other types of mol-
ecules such as activators or allosteric ligands, which do
not reduce activity, would be more appropriate [1-3].
There is a limit in this approach because not all the ge-
notypes of a given disease are eligible for therapy with
PC and only in some cases is it possible to predict the
responsiveness of specific mutations [4].
Drug repositioning could accelerate the discovery of PC.
The first successful case is provided by imino-sugars that
interfere with N-glycosylation in cells infected by envel-
oped viruses, deoxynojirimcin and its derivatives [5].
Clinical trials for the treatment of HIV with deoxynojirim-
cines were unsuccessful, because the antiviral concentra-
tion required could not be achieved in humans. However
the same imino-sugars could be used as PC at low concen-
tration for a different target, glucosylceramidase (Uniprot:
P04062), to treat Gaucher disease (MIM: 230800) [6] and
lysosomal alpha-glucosidase (Uniprot: P10253), to treat
Pompe disease (MIM: 232300) [7,8]. The usage of imino-* Correspondence: giuseppina.andreotti@icb.cnr.it; cubellis@unina.it
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to cure some storage disorders.
Drug repositioning should be run systematically for
the discovery of PC. To support our proposal we gath-
ered all the proteins that are associated to rare diseases,
i.e. the entries that have a link to Orphanet [9] in Uni-
prot (Orphan_proteins). For 608 entries out of a total of
3289 Orphan_proteins we found a link to DrugBank, a
database including FDA-approved small molecules, ex-
perimental and nutraceuticals drugs [10]. DrugBank an-
notates each record with the known pharmacological
protein target, but also with other proteins that are acti-
vated or inhibited by the drug. In the vast majority of
cases, links between Orphan_proteins and drugs only
indicate relations documented in the literature, but do
not implicate a recognized pharmacological action of the
drug on the target. The histogram in Figure 1 shows
that several Orphan_proteins interact with one or more
approved small molecules and the list is provided in
Additional file 1. Since our aim is to support the
usefulness of repositioning, we excluded biotech drugs
because some of them have already been approved for
enzyme replacement therapy of rare diseases. We also
excluded cytochromes, which contribute to the metabol-
ism of many drugs. Small chemicals that interact with
Orphan_proteins are excellent starting points to develop
PC. A proof of concept is represented by a paper whichral. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Orphan_Protein distribution per drug. Proteins associated
to rare diseases are ordered by a number of interacting small molecule
FDA-approved drugs.
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drugs from commercial compound libraries led to the
identification of Ibuprofen as a corrector of the transmem-
brane conductance regulator (CFTR) (Uniprot: P13569).
Ibuprofen has a pharmacological action on Prostaglandin
synthase 1 and 2 (Uniprot: P35354, P23219), but besides
this action, DrugBank reports the inhibition of CFTR
based on a paper published in 1998 [12].
In addition, we found several other cases in which
small approved drugs were successfully repositioned as
PC for rare diseases: doxorubicin, an anti-neoplastic
anthracycline, for Cystic fibrosis (MIM: 219700) [13],
Diltiazem, an antihypertensive, for Gaucher disease
(MIM: 230800) [14], Ambroxol, a mucolytic agent, for
Gaucher and for Fabry disease (MIM: 301500) [15,16],
Acetylcysteine, another mucolytic agent, for Pompe dis-
ease (MIM: 232300) [17], Pyrimethamine, an anti-parasitic
compound, for GM2 gangliosidosis (MIM: 272800) [18],
carbamazepine, a dibenzazepine, for Hyperinsulinemic
Hypoglycemia (MIM: 256450) [19] and Salicylate for Pen-
dred Syndrome (MIM: 274600) [20].
In these cases, however, the link between the drug and
the Orphan_protein, could not be found in DrugBank.
This absence of annotation shows how difficult it is to
mine the literature and we admit that also our list of
approved drugs tested as PC may be incomplete. The
development of drugs for rare diseases would benefit
from a mechanism that favours the deposition of data
concerning the interaction of small molecules and pro-
teins into databanks.Additional file
Additional file 1: Orphan_Proteins associated to approved small
molecules are listed. The column headings are: Entry, Uniprot ID; Entry
Name, Uniprot entry name; Status, reviewed if SWISS-Prot entry; Protein
names, protein full name; Gene names, Names of each gene associated to the
protein; DrugBank cross-reference, List of drugs associated (by DrugBankID);
Orphanet cross-reference: List of orphan diseases (by OrphanID) associated to
the protein.
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